Long-term prostaglandin E1therapy in congenital heart defects

Long-term symptoms of depression and anxiety in mothers of infants with congenital heart defects.

OBJECTIVE To examine the relationship between the severity of infants' congenital heart defects (CHD) and their mothers' symptoms of depression and anxiety from pregnancy to 18 months postpartum. METHODS Mothers of infants with mild, moderate, or severe CHD (n=162) and mothers (n=44,400) within the Norwegian Mother and Child Cohort Study were assessed with an eight-item short version (SCL-8) ...

Congenital heart defects in adulthood.

BACKGROUND More than 90% of children with congenital heart defects now survive into adulthood; just a few decades ago, survival was rare, particularly among patients with complex defects. The new population of adults with congenital heart disease presents a special challenge to physicians from all of the involved specialties. METHODS Selective literature review. RESULTS AND CONCLUSION A com...

Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects.

BACKGROUND Although long-term prostacyclin (PGI2) has been shown to improve hemodynamics, quality of life, and survival in patients with primary pulmonary hypertension, its use in patients with pulmonary hypertension (PHT) and associated congenital heart defects (CHD) has not been evaluated. METHODS AND RESULTS Twenty patients (15+/-14 years) with PHT and associated CHD (9 atrial septal defec...

Congenital Heart Disease Congenital Heart Defects in Europe

Background—This study determines the prevalence of Congenital Heart Defects (CHD), diagnosed prenatally or in infancy, and fetal and perinatal mortality associated with CHD in Europe. Methods and Results—Data were extracted from the European Surveillance of Congenital Anomalies central database for 29 population-based congenital anomaly registries in 16 European countries covering 3.3 million b...

Long-term outlook in treated congenital heart disease.